CN Patent

CN101677972A — 一种用于治疗神经变性疾病的奈拉美生的新组合物

Assigned to Merz Pharma GmbH and Co KGaA · Expires 2010-03-24 · 16y expired

What this patent protects

本发明涉及包含奈拉美生和谷氨酸盐释放抑制剂(GRI)的组合物，以及这种组合物在治疗神经变性疾病中的应用。

USPTO Abstract

本发明涉及包含奈拉美生和谷氨酸盐释放抑制剂(GRI)的组合物，以及这种组合物在治疗神经变性疾病中的应用。

Drugs covered by this patent

cetirizine-hydrochloride (CETIRIZINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN101677972A
Jurisdiction: CN
Classification: —
Expires: 2010-03-24
Drug substance claim: No
Drug product claim: No
Assignee: Merz Pharma GmbH and Co KGaA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.